Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Matteo Rosellini, Andrea Marchetti, Veronica Mollica, et al.
Nature Reviews Urology (2022) Vol. 20, Iss. 3, pp. 133-157
Closed Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 134
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5039-5049
Closed Access | Times Cited: 124
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1381-1394
Closed Access | Times Cited: 112
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 29
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
Giulia Marvaso, Barbara Alicja Jereczek‐Fossa, Mattia Zaffaroni, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. e193-e204
Closed Access | Times Cited: 15
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Guihong Wan, Wenxin Chen, Sara Khattab, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1053-1069
Closed Access | Times Cited: 15
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Tejas Jammihal, Renée Maria Saliby, Chris Labaki, et al.
Nature Cancer (2025)
Open Access | Times Cited: 4
TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma
Yawei Xu, Lei Li, Wuping Yang, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 32
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, et al.
Biomolecules (2023) Vol. 13, Iss. 12, pp. 1803-1803
Open Access | Times Cited: 23
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K. Choueiri, Jaime R. Merchan, Robert A. Figlin, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 64-73
Closed Access | Times Cited: 1
NanoTrackThera Platform for Real‐Time, In Situ Monitoring of Tumor Immunotherapy and Photothermal Synergistic Efficacy
Zixuan Chang, Keyi Wang, Zhou Fang, et al.
Small (2025)
Closed Access | Times Cited: 1
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study
Laurence Albigès, Marine Gross‐Goupil, Philippe Barthélémy, et al.
European Urology Oncology (2025)
Closed Access | Times Cited: 1
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment
Shawna R. Calhoun, Caroline Vass, Kelley Myers, et al.
Future Oncology (2025), pp. 1-9
Open Access | Times Cited: 1
Diagnostic liquid biopsy biomarkers in renal cell cancer
Richard C. Zieren, Patricia Zondervan, Kenneth J. Pienta, et al.
Nature Reviews Urology (2023) Vol. 21, Iss. 3, pp. 133-157
Closed Access | Times Cited: 17
Immune and inflammatory mechanisms and therapeutic targets of gout: An update
Wenji Liu, Jie Peng, Yixin Wu, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110466-110466
Closed Access | Times Cited: 16
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care
Yao Xiao, Zi‐Zhan Li, Nian‐Nian Zhong, et al.
Translational Oncology (2023) Vol. 38, pp. 101794-101794
Open Access | Times Cited: 16
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Matthew Young, José Carlos Tapia, Bernadett Szabados, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 3, pp. 102072-102072
Closed Access | Times Cited: 7
Assessing and mitigating batch effects in large-scale omics studies
Ying Yu, Yuanbang Mai, Yuanting Zheng, et al.
Genome biology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
Niklas Klümper, Alexander Cox, Markus Eckstein, et al.
European Journal of Cancer (2024) Vol. 204, pp. 114089-114089
Open Access | Times Cited: 6
Next-generation cancer vaccines and emerging immunotherapy combinations
Anne Brandenburg, Annkristin Heine, Peter Brossart
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 749-769
Closed Access | Times Cited: 6
Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients
Lei Ren, Jinwen Liu, Qingyuan Lin, et al.
BMC Genomics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina‐Cerrillo, Francesco Massari, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era?
Andrea Marchetti, Veronica Mollica, Stefano Brocchi, et al.
Expert Review of Molecular Diagnostics (2025)
Open Access
A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer
Maike Zheng, Mingming Hu, Yanxia Liu, et al.
Biomarker Insights (2025) Vol. 20
Open Access
Development and validation of prognostic and diagnostic models utilizing immune checkpoint-related genes in public datasets for clear cell renal cell carcinoma
Bin Zhao, Shi Fu, Yuanlong Shi, et al.
Frontiers in Genetics (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top